바이넥스

053030KOSDAQ의약품 제조업

36.3 / 100

Reference Date: 2026-04-13

Financial Score7.0 / 40

News Sentiment16.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Declined 14.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Bionex is a biopharmaceutical CDMO company that produces chemical pharmaceuticals at its Busan factory and expanded production capacity threefold with a new facility in 2023. Its chemical business unit focuses on ointments and eye drops, securing market share with proprietary products, while biopharmaceutical CDMO services accounted for 46.72% of revenue in 2025. The company has established cGMP-compliant systems and passed global GMP inspections to grow as a global CDMO.

Number of Employees

791people

Average Salary

49.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

1.94Industry Average 1.041.0Point

1.9x industry avg (risky)

ROE

-1.78Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

32.71Industry Average 11.980.0Point

2.7x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼1482.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -6.2% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 65

Positive
바이넥스, 바이오시밀러 품목 다변화로 중장기 수혜 분명 -IBK
IBK투자증권은 바이넥스가 바이오시밀러 품목 다변화와 바이오 CDMO 매출 증가로 2025년 매출액이 크게 증가하고 영업손실이 축소될 것으로 전망하며 중장기 수혜를 예상했습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 11,130Won52-week high 18,93052-week low 10,700

1-month return1.0Point

1m -14.71% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
Neutral주식등의대량보유상황보고서(일반)2026-03-27
Neutral정기주주총회결과2026-03-23